Ankylos® implant system – Clinical documentation

Well documented, reliable and safe
- More than 17,000 patients followed up to 20 years
- 97% implant survival rate after 5 years or more of follow-up
- Stable bone levels after 5 to 12 years of follow-up

The TissueCare Concept behind the clinical success
The Ankylos implant system is scientifically and clinically proven to maintain hard and soft tissue over time, with excellent esthetics and high patient satisfaction. This is achieved by the unique combination of the following features:
- SoftTissue Chamber – subcrestal placement in combination with the horizontal offset creates the chamber supporting stable soft tissue and bone
- Friadent plus surface – microstructured surface on the implant shoulder
- One-fits-all TissueCare connection – one conical implant-abutment connection
- Progressive Thread – transferring the load to the apical parts of the implant

Clinical results
Published data shows that placement of Ankylos implants is safe and predictable in both jaws, for indications such as:

<table>
<thead>
<tr>
<th></th>
<th>No. of patients</th>
<th>No. of implants</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate loading</td>
<td>&gt;2000</td>
<td>&gt;5500</td>
<td>6–14, 16–38</td>
</tr>
<tr>
<td>Single tooth</td>
<td>&gt;1700</td>
<td>&gt;2300</td>
<td>9, 10, 14, 19–22, 27–29, 37, 39–48</td>
</tr>
<tr>
<td>Fixed prosthesis</td>
<td>&gt;900</td>
<td>&gt;2800</td>
<td>6, 8, 10, 11, 14, 17, 18, 23–25, 31, 32, 36, 49–51</td>
</tr>
<tr>
<td>Overdenture</td>
<td>&gt;500</td>
<td>&gt;180</td>
<td>1, 4, 12, 13, 16, 30, 33, 34, 38, 52–59</td>
</tr>
<tr>
<td>Extraction sockets</td>
<td>&gt;500</td>
<td>&gt;900</td>
<td>18–22, 25, 34, 35, 37, 60</td>
</tr>
</tbody>
</table>

Further topics and concepts, such as intra-oral welding and implant stability are also well documented. Bone level evaluation show stable results.

The conometric concept with friction-retained restorations, has also been evaluated with the Ankylos implant system, showing promising results.

Conclusion
Extensive literature evaluating over 55,000 implants, shows safe and predictable treatment outcomes for the Ankylos implant system, with >97% implant survival rate after 5 years or more of follow-up.

To read more Scientific Reviews please see: www.dentsplysirona.com/implants/science
References


To read more Scientific Reviews please see: www.dentsplysirona.com/implants/science


About Dentsply Sirona Implants

Dentsply Sirona Implants offers comprehensive solutions for all phases of implant therapy, including Ankylos®, Astra Tech Implant System® and Xive® implant lines, digital technologies, such as Atlantis® patient-specific solutions and Simplant® guided surgery, Symbios® regenerative solutions, and professional and business development programs, such as STEPPS™. Dentsply Sirona Implants creates value for dental professionals and allows for predictable and lasting implant treatment outcomes, resulting in enhanced quality of life for patients.

About Dentsply Sirona

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 130-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company™, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. Dentsply Sirona’s global headquarters is located in York, Pennsylvania, and the international headquarters is based in Salzburg, Austria. The company’s shares are listed in the United States on NASDAQ under the symbol XRAY.

Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.